Literature DB >> 16051032

Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas.

Beatriz S Stolf1, Cintia M Abreu, Maria B Mahler-Araújo, Márcia Dellamano, Waleska K Martins, Marcos Brasilino de Carvalho, Maria P Curado, Juan P Díaz, Artur Fabri, Helena Brentani, Alex F Carvalho, Fernando A Soares, Luiz P Kowalski, Roberto Hirata, Luiz F L Reis.   

Abstract

Using cDNA microarrays with 3800 cDNA fragments, we determined the expression profile of normal thyroid tissue, goiter, adenoma and papillary carcinoma (10 samples from each class). After background correction and statistical analysis, we identified a set of 160 genes as being differentially expressed in all pair-wise comparisons. Here we demonstrate that, at least on the basis of these differentially expressed genes, a positive correlation between goiter and papillary carcinomas could be observed. We identified a common set of genes whose expression is diminished in both goiter and papillary carcinomas as compared to normal thyroid tissue. Moreover, no genes with inverse correlation in samples from goiter and papillary carcinomas could be detected. Using Real-Time PCR and/or tissue microarrays, we confirmed the altered expression of some of the identified genes. Of notice, we demonstrate that the reduced mRNA levels of p27(kip1) observed in papillary carcinomas as compared to either goiter or normal thyroid tissues (P<0.001) is accompanied by an altered protein distribution within the cell. In papillary carcinomas, P27(KIP1) is preferentially cytoplasmic as opposed to goiter or normal thyroid tissue, where P27(KIP1) is preferentially located in the nucleus. The exploitation of the data presented here could contribute to the understanding of the molecular events related to thyroid diseases and gives support to the notion that common molecular events might be related to the frequent observation of areas of papillary carcinomas in the gland of patients with goiter.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16051032     DOI: 10.1016/j.canlet.2004.11.050

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  5 in total

1.  Differential gene expression profile of multinodular goiter.

Authors:  Wenberger Lanza Daniel de Figueiredo; Eraldo Ferreira Lopes; Deborah Laredo Jezini; Lorena Naciff Marçal; Enedina Nogueira de Assunção; Paulo Rodrigo Ribeiro Rodrigues; Adolfo José da Mota; Diego Monteiro de Carvalho; Spartaco Astolfi Filho; João Bosco Lopes Botelho
Journal:  PLoS One       Date:  2022-05-20       Impact factor: 3.752

2.  Expression of p21cip1, p27kip1, and p16INk4a cyclin-dependent kinase inhibitors in papillary thyroid carcinoma: correlation with clinicopathological factors.

Authors:  Carles Zafon; Gabriel Obiols; Josep Castellví; Santiago Ramon y Cajal; Juan Antonio Baena; Jordi Mesa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

3.  Forkhead box K1 facilitates growth of papillary thyroid carcinoma cells by regulating connective tissue growth factor expression.

Authors:  Hongwei Xu; Yang Liu; Zheng Liu; Xiaoming Wang; Xiubo Lu
Journal:  Hum Cell       Date:  2020-10-24       Impact factor: 4.174

4.  Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy.

Authors:  S P Finn; P Smyth; S Cahill; C Streck; E M O'Regan; R Flavin; J Sherlock; D Howells; R Henfrey; M Cullen; M Toner; C Timon; J J O'Leary; O M Sheils
Journal:  Virchows Arch       Date:  2007-01-25       Impact factor: 4.064

5.  Increasing the number of thyroid lesions classes in microarray analysis improves the relevance of diagnostic markers.

Authors:  Jean-Fred Fontaine; Delphine Mirebeau-Prunier; Mahatsangy Raharijaona; Brigitte Franc; Stephane Triau; Patrice Rodien; Olivier Goëau-Brissonniére; Lucie Karayan-Tapon; Marielle Mello; Rémi Houlgatte; Yves Malthiery; Frédérique Savagner
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.